Retrospective Descriptive Study of Platelet Transfusion in Patients With Palliative Hematologic Malignancies at the University Hospital of Besançon

Etude Descriptive Retrospective de la Transfusion Plaquettaire Chez Des Patients Atteints d'hémopathie Maligne en Phase Palliative et Suivis au CHU de Besançon

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03814486

Enrollment

119

Registered

2019-01-24

Start date

2017-07-01

Completion date

2018-07-01

Last updated

2019-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Palliative Care, Platelet Transfusion

Keywords

platelet transfusion, palliative care

Brief summary

Development of palliative care is less effective for patients with hematologic malignancies. Limited data is available for end of life care in this population, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. Yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. As it represent a scarce, limited resource, the ethical principles are in conflict in this setting. The purpose of this study was to describe retrospectively platelet transfusion in the six last few month of life of patients with hematologic malignancies at the CHU of Besançon (France) between 01/07/15 and 31/12/16.

Interventions

OTHERdescriptive

evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patient with hematological malignancies * transfused in platelet at least once in the last 6 months of life * hospitalised or follow up at the CHU of Besancon at least once * dead during the period of the study

Exclusion criteria

* patient with other oncologic malignancies * not transfused in platelet in the last 6 months of life * never hospitalised or follow up at the CHU of Besancon * alive

Design outcomes

Primary

Measure	Time frame	Description
evaluate frequency of platelet transfusion at the end of life	18 months (between 07/01/2015 and 12/31/2016)	to calculate the number of platelet transfusion at the end of life. The number of platelet transfusion between 6 months and death are collected in each periods of 2 weeks to calculate the number of transfusion per patient during each 2 weeks.
evaluate efficacy of prophylactic platelet transfusion at the end of life	18 months (between 07/01/2015 and 12/31/2016)	to calculate the platelet yield in percentage
evaluate efficacy of non prophylactic platelet transfusion at the end of life	18 month (between 07/01/2015 and 12/31/2016)	to calculate the transfusional interval between 2 platelet transfusion in days

Secondary

Measure	Time frame	Description
demographic characteristic	18 months (between 07/01/2015 and 12/31/2016)	characteristic of patient (age, diagnosis,location of death, palliative care received...)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026